Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH W KIM

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1295913531
CMS profile
331552
Location
NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$10,547.28

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,310.00 2
Travel and Lodging $1,506.97 3
Food and Beverage $730.31 8

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $9,077.84 9
Janssen Scientific Affairs, LLC $1,100.00 1
Dendreon Pharmaceuticals LLC $215.29 2
Genentech USA, Inc. $154.15 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH W KIM

NPI 1295913531 · CMS profile ID 331552

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295913531?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH W KIM, NPI 1295913531, CMS profile ID 331552. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295913531?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOSEPH W KIM, NPI 1295913531, CMS profile ID 331552. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295913531?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOSEPH W KIM, NPI 1295913531, CMS profile ID 331552, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1295913531?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $10,547.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $1,100.0012/07/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887192001 CMS
GENZYME CORPORATION $7,210.0010/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939053613 CMS
GENZYME CORPORATION $1,167.5910/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939053615 CMS
GENZYME CORPORATION $289.3810/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939053617 CMS
GENZYME CORPORATION $140.0010/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939053619 CMS
GENZYME CORPORATION $47.7310/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939053621 CMS
GENZYME CORPORATION $65.0010/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939053623 CMS
GENZYME CORPORATION $35.0010/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939053625 CMS
GENZYME CORPORATION $73.1410/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939053627 CMS
GENZYME CORPORATION $50.0010/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939053629 CMS
Dendreon Pharmaceuticals LLC $36.5206/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943101851 CMS
Dendreon Pharmaceuticals LLC $178.7702/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943101849 CMS
Genentech USA, Inc. $154.1502/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950690719 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,478.38 10
PY2020 $3,374.14 4
PY2021 $585.00 1
PY2022 $10,547.28 13
PY2023 $1,967.17 5
PY2024 $155.03 2
PY2025 $212.94 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $314.64 2
PY2025 Principal investigator $1,110,282.24 135
PY2024 Recipient $191.83 1
PY2024 Principal investigator $346,888.51 69
PY2023 Principal investigator $403,164.02 48
PY2022 Principal investigator $107,144.09 26
PY2021 Recipient $1,076.26 1
PY2021 Principal investigator $36,646.51 15
PY2020 Recipient $1,914.15 1
PY2020 Principal investigator $48,418.68 17
PY2019 Principal investigator $33,029.40 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,136.14 12/19/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977205983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,469.62 12/12/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977203369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 12/08/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977203015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,988.70 12/08/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977203021
Principal investigator 1 Merck Sharp & Dohme LLC $39,050.00 11/28/2023 Non-covered Recipient Entity
Yale Cancer Center
A Phase 1 Study of HMBD-002-V4C26 HMBD-002, a Monoclonal Antibody Targeting VISTS, as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced Solid Malignancies No dispute reported 06/30/2026 1042489139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,809.09 11/28/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977199955
Principal investigator 1 Genentech, Inc. $250.00 11/21/2023 Non-covered Recipient Entity
YALE UNIVERSITY SCHOOL OF MEDICINE
PHASE I DOSE ESCALATION STUDY OF RO7444973 ON SOLID TUMOURS No dispute reported 06/30/2026 1040652958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,309.80 11/21/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977197607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,988.70 11/17/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977197045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.30 11/07/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977195491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,550.09 11/02/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977194569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,044.79 10/25/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977190163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $189.80 10/10/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977187441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,309.80 10/10/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977187459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,200.00 10/03/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977185867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.30 10/03/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977186391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,988.70 10/03/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977186397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,168.29 09/21/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977182629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,179.59 09/12/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977182031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,976.50 09/01/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977179817
Principal investigator 1 ADC Therapeutics America, Inc. $390.00 08/25/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209957
Principal investigator 1 ADC Therapeutics America, Inc. $1,787.50 08/25/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209959
Principal investigator 1 ADC Therapeutics America, Inc. $1,787.50 08/25/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $130,840.79 08/10/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977177323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 07/26/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977171603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 07/26/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977171621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 06/28/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977151503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $780.00 05/11/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977109279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,900.00 05/11/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977109285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,458.70 05/09/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977107623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28,235.79 04/26/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977105345
Principal investigator 1 ADC Therapeutics America, Inc. $455.00 03/31/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209949
Principal investigator 1 Genentech, Inc. $25,009.40 03/20/2023 Non-covered Recipient Entity
YALE UNIVERSITY SCHOOL OF MEDICINE
PHASE I DOSE ESCALATION STUDY OF RO7444973 ON SOLID TUMOURS No dispute reported 06/30/2026 1040652989
Principal investigator 1 Genentech, Inc. $1,800.00 03/06/2023 Non-covered Recipient Entity
YALE UNIVERSITY SCHOOL OF MEDICINE
PHASE I DOSE ESCALATION STUDY OF RO7444973 ON SOLID TUMOURS No dispute reported 06/30/2026 1040652973
Principal investigator 1 ADC Therapeutics America, Inc. $682.50 03/02/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209947
Principal investigator 1 ADC Therapeutics America, Inc. $682.50 03/02/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,679.60 02/22/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977093103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,993.99 02/16/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977092301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,420.60 02/09/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977091161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,732.44 01/25/2023 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 977088835
Principal investigator 1 Exelixis Inc. $702.00 01/13/2023 Non-covered Recipient Entity
Yale University
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041953801
Principal investigator 1 Exelixis Inc. $2,925.00 01/13/2023 Non-covered Recipient Entity
Yale University
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041953817
Principal investigator 1 ADC Therapeutics America, Inc. $990.60 01/06/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209939
Principal investigator 1 ADC Therapeutics America, Inc. $2,497.30 01/06/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209941
Principal investigator 1 ADC Therapeutics America, Inc. $3,719.30 01/06/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209943
Principal investigator 1 ADC Therapeutics America, Inc. $2,545.40 01/06/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209945
Principal investigator 1 ADC Therapeutics America, Inc. $990.60 01/06/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209953
Principal investigator 1 ADC Therapeutics America, Inc. $2,497.30 01/06/2023 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1051209955